Previous close | 0.1529 |
Open | 0.1530 |
Bid | 0.1525 x 0 |
Ask | 0.1582 x 0 |
Day's range | 0.1530 - 0.1640 |
52-week range | 0.0560 - 0.2250 |
Volume | |
Avg. volume | 231,065 |
Market cap | 66.368M |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
KNOXVILLE, Tenn., June 13, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that its 2024 annual stockholder meeting (the “2024 Annual Meeting”), including meeting activities and a company update, will be accessible by Zoom Webinar. The meeting will be held on Thursday, June 20, 2024 at the Hilton Knoxville, located at 501 West Church Avenue, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time. The 2024 Annual Meeting webi
Accelerates wound closure and improves wound healing KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharmaceutical-grade, rose bengal sodium (“RBS”) active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology (“SID”), held May 15-18, 20
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose bengal photodynamic antimicrobial therapy (“RB PDAT”) were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (“ARVO”), held May 5-9, 2024 in Seattle, Washington. The ARVO annual meeting brings togeth